Navigation Links
Alba Therapeutics Appoints Wendy Perrow Chief Executive Officer
Date:11/5/2013

BALTIMORE, Nov. 5, 2013 /PRNewswire/-- Alba Therapeutics Corporation today announced the appointment of Wendy Perrow as its Chief Executive Officer (CEO).  Her responsibilities include managing the Company's business, clinical, financial, licensing, and corporate development efforts.  Ms. Perrow previously served as President and COO and she has been a member of Alba's executive management team since 2008.

Under her leadership, Alba Therapeutics established a collaborative funding agreement on February 9, 2011 with Cephalon Pharmaceuticals (now Teva Pharmaceuticals) and has taken a leading role in advancing multiple clinical studies in Celiac Disease.  The company has conducted seven clinical trials in subjects with Celiac Disease and is currently conducting a large Phase IIb trial with the lead compound Larazotide Acetate. 

"Ms. Perrow brings a wealth of global experience and leadership with a proven track record of success in both biotech and pharmaceutical companies," said Bruce Peacock Co-Chairman of Alba. "Wendy is a key member of our leadership team, driving deal making as well as clinical and financial strategy and her experience in leading successful research and development and commercial infrastructures has been invaluable to Alba."

Prior to joining Alba, Ms. Perrow held senior executive marketing positions with private and public pharmaceutical companies. From 2004 to 2007, she was Vice President of Marketing for Sigma-Tau Pharmaceuticals, Inc., a company focused on creating novel therapies for the unmet needs of patients with rare diseases. From 1989 to 2003, Ms. Perrow was at Merck and Co., Inc. in Global and U.S. marketing for Anti-Hypertensives, Vaccines, Cholesterol, and GI. At Merck, she held positions in marketing promotion, international business research analysis, training, and sales. Ms. Perrow began her career in a division of Johnson & Johnson. A skilled marketer and business leader, she has led U.S. and Global initiatives for leading products that have significantly increased brand awareness and has launched medicines for unmet medical needs.

"Throughout her career, Ms. Perrow has demonstrated a true passion and commitment to bring new scientific advances and medications to help improve the standard of care for patients who have rare and serious conditions around the globe," said Matt Zuga Co-Chairman of Alba.  "With her broad experience and proven leadership across research, development, and commercialization, we have been able to accelerate Alba's mission to create medicines for patients with Celiac Disease.  Her breadth of experience in building successful companies and establishing strong collaborations is a tremendous asset to Alba Therapeutics as we continue to establish our leadership position in the Celiac Disease field."

Ms. Perrow holds a bachelor's degree from Eastern Illinois University and a Masters of Business Administration degree in finance and marketing from Duke University - The Fuqua School of Business.

About Alba
Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland.


'/>"/>
SOURCE Alba Therapeutics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... -- Patients in Alabama seeking prostate care ... longer have to travel out of state. Vituro Health ... Centers of Alabama to provide a total prostate management ... Alabama is known throughout ... cancer using many different modalities. They are the largest and ...
(Date:2/5/2016)... Aethlon Medical, Inc. (Nasdaq: AEMD ), today ... be presenting at Source Capital Group,s 2016 Disruptive Growth & ... at 2:15 p.m. ET on Wednesday, February 10, 2016.  Mr. ... place at 3:15 p.m. ET. http://www.aethlonmedical.com .  The ... the conclusion of the live event. The panel discussion will ...
(Date:2/5/2016)... 5, 2016 Dehaier Medical Systems Ltd. ... "Company"), which develops, markets and sells medical devices ... China and international markets, today announced ... to concentrate the Company,s resources to develop its ... and to focus more on its major businesses. ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Steven Tonkinson, 36, of Coconut Grove, ... year since it started in 2003. This year, he ran all 26.2 miles with ... and NBA team the Miami Heat. , This Sunday, while many are watching the ...
(Date:2/5/2016)... Falls, NY & Salt Lake City, UT (PRWEB) , ... February ... ... Davis, Founder of Activz Whole-Food Nutrition , announced that the much-anticipated feature with ... on the New Really Cool Humans Amateur TV Network. , Each week, on his ...
(Date:2/5/2016)... ... 2016 , ... The Muscular Dystrophy Association and Sailormen Inc., ... 14th annual “Appetite for a Cure” campaign on Feb. 1 to raise critical ... diseases that severely limit strength and mobility. , Now through March 20, ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... President George H. Van Allen have signed a joint enrollment and degree completion ... seamless pathway toward associate and baccalaureate degrees at FHU|Dickson. , The agreement ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... US ... Yoga Studio in Dover, NH to direct high-performance kids yoga training. ChildLight Yoga Studio ... seacoast, just one hour from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses ...
Breaking Medicine News(10 mins):